A meta-analysis of the effects of β-adrenergic blockers in chronic heart failure

Zhang,Xiaojian; Shen,Chengwu; Zhai,Shujun; Liu,Yukun; Yue,Wen‑Wei; Han,Li

doi:10.3892/etm.2016.3657

A meta-analysis of the effects of β-adrenergic blockers in chronic heart failure

Authors:
- Xiaojian Zhang
- Chengwu Shen
- Shujun Zhai
- Yukun Liu
- Wen‑Wei Yue
- Li Han
View Affiliations

Affiliations: Shandong Provincial Hospital Affiliated to Shandong University, Ji'nan, Shandong 250021, P.R. China, Laiwu Health School, Laiwu, Shandong 271100, P.R. China, The Fourth People's Hospital of Ji'nan, Ji'nan, Shandong 250021, P.R. China
Published online on: September 5, 2016 https://doi.org/10.3892/etm.2016.3657
Pages: 2489-2496
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adrenergic β‑blockers are drugs that bind to, but do not activate β‑adrenergic receptors. Instead they block the actions of β-adrenergic agonists and are used for the treatment of various diseases such as cardiac arrhythmias, angina pectoris, myocardial infarction, hypertension, headache, migraines, stress, anxiety, prostate cancer, and heart failure. Several meta‑analysis studies have shown that β‑blockers improve the heart function and reduce the risks of cardiovascular events, rate of mortality, and sudden death through chronic heart failure (CHF) of patients. The present study identified results from recent meta‑analyses of β‑adrenergic blockers and their usefulness in CHF. Databases including Medline/Embase/Cochrane Central Register of Controlled Trials (CENTRAL), and PubMed were searched for the periods May, 1985 to March, 2011 and June, 2013 to August, 2015, and a number of studies identified. Results of those studies showed that use of β‑blockers was associated with decreased sudden cardiac death in patients with heart failure. However, contradictory results have also been reported. The present meta‑analysis aimed to determine the efficacy of β‑blockers on mortality and morbidity in patients with heart failure. The results showed that mortality was significantly reduced by β‑blocker treatment prior to the surgery of heart failure patients. The results from the meta‑analysis studies showed that β‑blocker treatment in heart failure patients correlated with a significant decrease in long‑term mortality, even in patients that meet one or more exclusion criteria of the MERIT‑HF study. In summary, the findings of the current meta-analysis revealed beneficial effects different β‑blockers have on patients with heart failure or related heart disease.

View Figures

View References

1	Lechat P, Packer M, Chalon S, Cucherat M, Arab T and Boissel JP: Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation. 98:1184–1191. 1998. View Article : Google Scholar : PubMed/NCBI
2	Packer M: The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 20:248–254. 1992. View Article : Google Scholar : PubMed/NCBI
3	Doughty RN, Rodgers A, Sharpe N and MacMahon S: Effects of beta-blocker therapy on mortality in patients with heart failure: A systematic overview of randomized controlled trials. Eur Heart J. 18:560–565. 1997. View Article : Google Scholar : PubMed/NCBI
4	Heidenreich PA, Lee TT and Massie BM: Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 30:27–34. 1997. View Article : Google Scholar : PubMed/NCBI
5	Al-Gobari M, El Khatib C, Pillon F and Gueyffier F: β-Blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 13:522013. View Article : Google Scholar : PubMed/NCBI
6	DerSimonian R and Laird N: Meta-analysis in clinical trials. Control Clin Trials. 7:177–188. 1986. View Article : Google Scholar : PubMed/NCBI
7	Higgins JPT, Thompson SG, Deeks JJ and Altman DG: Measuring inconsistency in meta-analyses. BMJ. 327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
8	Anderson JL, Lutz JR, Gilbert EM, Sorensen SG, Yanowitz FG, Menlove RL and Bartholomew M: A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol. 55:471–475. 1985. View Article : Google Scholar : PubMed/NCBI
9	Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ and McQuay HJ: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 17:1–12. 1996. View Article : Google Scholar : PubMed/NCBI
10	Piccini JP, Berger JS and O'Connor CM: Amiodarone for the prevention of sudden cardiac death: A meta-analysis of randomized controlled trials. Eur Heart J. 30:1245–1253. 2009. View Article : Google Scholar : PubMed/NCBI
11	Beta-Blocker Evaluation of Survival Trial Investigators: A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 344:1659–1667. 2001. View Article : Google Scholar : PubMed/NCBI
12	No authors listed: Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet. 349:375–380. 1997. View Article : Google Scholar : PubMed/NCBI
13	Chadda K, Goldstein S, Byington R and Curb JD: Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation. 73:503–510. 1986. View Article : Google Scholar : PubMed/NCBI
14	Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G and Kelly P: Bucindolol Investigators: Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. Circulation. 89:1632–1642. 1994. View Article : Google Scholar : PubMed/NCBI
15	Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, et al: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 94:2807–2816. 1996. View Article : Google Scholar : PubMed/NCBI
16	Dargie HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 357:1385–1390. 2001. View Article : Google Scholar : PubMed/NCBI
17	No authors listed: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomized trial. Lancet. 353:9–13. 1999. View Article : Google Scholar : PubMed/NCBI
18	No authors listed: A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation. 90:1765–1773. 1994. View Article : Google Scholar : PubMed/NCBI
19	Witchitz S, Cohen-Solal A, Dartois N, Weisslinger N, Juste K and Darmon JY: Treatment of heart failure with celiprolol, a cardioselective beta blocker with beta-2 agonist vasodilatory properties. The CELICARD Group. Am J Cardiol. 85:1467–1471. 2000. View Article : Google Scholar
20	Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, et al: Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation. 94:2800–2806. 1996.
21	Packer M, Fowler MB, Roecker EB, Coats AJS, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, et al: Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 106:2194–2199. 2002. View Article : Google Scholar : PubMed/NCBI
22	de Milliano PA, de Groot AC, Tijssen JG, van Eck-Smit BL, Van Zwieten PA and Lie KI: Beneficial effects of metoprolol on myocardial sympathetic function: Evidence from a randomized, placebo-controlled study in patients with congestive heart failure. Am Heart J. 144:E32002. View Article : Google Scholar : PubMed/NCBI
23	Conraads VM, Metra M, Kamp O, De Keulenaer GW, Pieske B, Zamorano J, Vardas PE, Böhm M and Dei Cas L: Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail. 14:219–225. 2012. View Article : Google Scholar : PubMed/NCBI
24	Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ and Gunnar RM: Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: A double-blind, randomized, placebo-controlled trial. Circulation. 72:536–546. 1985. View Article : Google Scholar : PubMed/NCBI
25	Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK and Hamilton BP: Beneficial effects of metoprolol in heart failure associated with coronary artery disease: A randomized trial. J Am Coll Cardiol. 23:943–950. 1994. View Article : Google Scholar : PubMed/NCBI
26	Hansteen V, Møinichen E, Lorentsen E, Andersen A, Strøm O, Søiland K, Dyrbekk D, Refsum AM, Tromsdal A, Knudsen K, et al: One year's treatment with propranolol after myocardial infarction: Preliminary report of Norwegian multicentre trial. Br Med J (Clin Res Ed). 284:155–160. 1982. View Article : Google Scholar : PubMed/NCBI
27	Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, et al: Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 92:1499–1506. 1995. View Article : Google Scholar : PubMed/NCBI
28	Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG and Hjalmarson A: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 342:1441–1446. 1993.
29	No authors listed: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 353:2001–2007. 1999. View Article : Google Scholar : PubMed/NCBI
30	Metra M, Nardi M, Giubbini R and Dei Cas L: Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 24:1678–1687. 1994. View Article : Google Scholar : PubMed/NCBI
31	Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD and Bristow MR: Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study. J Am Coll Cardiol. 25:1225–1231. 1995. View Article : Google Scholar : PubMed/NCBI
32	Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM and Shusterman NH: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carve-dilol Heart Failure Study Group. N Engl J Med. 334:1349–1355. 1996.
33	Pollock SG, Lystash J, Tedesco C, Craddock G and Smucker ML: Usefulness of bucindolol in congestive heart failure. Am J Cardiol. 66:603–607. 1990. View Article : Google Scholar : PubMed/NCBI
34	No authors listed: Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies of left ventricular dysfunction pilot study. Circulation. 101:378–384. 2000. View Article : Google Scholar : PubMed/NCBI
35	Flather MD, Shibata MC, Coats AJS, van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, et al: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 26:215–225. 2005. View Article : Google Scholar : PubMed/NCBI
36	Sturm B, Pacher R, Strametz-Juranek J, Berger R, Frey B and Stanek B: Effect of beta 1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril. Eur J Heart Fail. 2:407–412. 2000. View Article : Google Scholar : PubMed/NCBI
37	Uhlir O, Dvorak I, Gregor P, Malek I, Spinarova L, Vojacek J and Van Nueten L: Nebivolol in the treatment of cardiac failure: A double-blind controlled clinical trial. J Card Fail. 3:271–276. 1997. View Article : Google Scholar : PubMed/NCBI
38	Wisenbaugh T, Katz I, Davis J, Essop R, Skoularigis J, Middlemost S, Röthlisberger C, Skudicky D and Sareli P: Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol. 21:1094–1100. 1993. View Article : Google Scholar : PubMed/NCBI
39	Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG and Menlove R: Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation. 84:2426–2441. 1991. View Article : Google Scholar : PubMed/NCBI
40	Bonet S, Agusti A, Arnau JM, Vidal X, Diogène E, Galve E and Laporte JR: Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients' characteristics: a meta-analysis of clinical trials. Arch Intern Med. 160:621–627. 2000. View Article : Google Scholar : PubMed/NCBI
41	Hanania NA, Singh S, El-Wali R, Flashner M, Franklin AE, Garner WJ, Dickey BF, Parra S, Ruoss S, Shardonofsky F, et al: The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther. 21:134–141. 2008. View Article : Google Scholar : PubMed/NCBI
42	Larochelle P, Tobe SW and Lacourcière Y: β-Blockers in Hypertension: studies and meta-analyses over the years. Can J Cardiol. 30 Suppl 5:S16–S22. 2014. View Article : Google Scholar : PubMed/NCBI
43	Matowa PR: Beta Blockers Use in Cardiac Failure: Does the Current Prescribing Practice at a Large Urban Hospital in Zimbabwe Exhibit Evidence Based Care and Offer Optimal Therapy for Cardiac Failure Patients? Pharmacology & Pharmacy. 6:267–279. 2015. View Article : Google Scholar
44	Bangalore S, Makani H, Radford M, Thakur K, Toklu B, Katz SD, DiNicolantonio JJ, Devereaux PJ, Alexander KP, Wetterslev J and Messerli FH: Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med. 127:939–953. 2014. View Article : Google Scholar : PubMed/NCBI
45	Bavishi C, Chatterjee S, Ather S, Patel D and Messerli FH: Beta-blockers in heart failure with preserved ejection fraction: A meta-analysis. Heart Fail Rev. 20:193–201. 2015. View Article : Google Scholar : PubMed/NCBI
46	Lu H, Liu X, Guo F, Tan S, Wang G, Liu H, Wang J, He X, Mo Y and Shi B: Impact of beta-blockers on prostate cancer mortality: a meta-analysis of 16,825 patients. Onco Targets Ther. 8:985–990. 2015. View Article : Google Scholar : PubMed/NCBI
47	Andrews TC, Reimold SC, Berlin JA and Antman EM: Prevention of supraventricular arrhythmias after coronary artery bypass surgery. A meta-analysis of randomized control trials. Circulation. 84 Suppl 5:III236–III244. 1991.
48	Chatterjee S, Biondi-Zoccai G, Abbate A, D'Ascenzo F, Castagno D, van Tassell B, Mukherjee D and Lichstein E: Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 346:f552013. View Article : Google Scholar : PubMed/NCBI
49	Ma ST, Zhao W, Liu B, Jia RY, Zhao CJ and Cui LQ: Association between β1 adrenergic receptor gene Arg389Gly polymorphism and risk of heart failure: a meta-analysis. Genet Mol Res. 14:5922–5929. 2015. View Article : Google Scholar : PubMed/NCBI
50	Mostafaie K, Bedenis R and Harrington D: Beta-adrenergic blockers for perioperative cardiac risk reduction in people undergoing vascular surgery. Cochrane Database Syst Rev. 1:CD0063422015.PubMed/NCBI